REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
10/03/2025
Voltar para busca
Dado oficial do USPTO
F
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: MistaEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
30
Atualização mais recente
10/03/2025
Classificação
Registrada
Tipo de marca
Mista
Classes Nice
1, 5, 9, 42
Data de depósito
06/07/2018
Data de registro
10/03/2020
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
10/03/2020
Última transação
10/03/2025
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Primeiro uso
19/11/2019
Primeiro uso no comércio
19/11/2019
Código do desenho
5
Tipo de titular
16
Localização do titular
Cambridge, MA
Examinador
BRADLEY, EVELYN
Unidade examinadora
L40
Localização atual
PUBLICATION AND ISSUE SECTION
Descrição da marca
The mark consists of a stylized "F' design.
Titulares e representantes
Titulares
Factor Bioscience LLC
Representantes
RACHELLE A. DUBOW, ESQ. MORGAN, LEWIS & BOCKIUS LLP
Classificação técnica
Classes Nice
Classe 1Classe 5Classe 9Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 1
Biochemicals in the nature of synthetic RNA encoding natural or engineered nucleaseszinc-finger nucleasesmeganucleasesnickasestranscription activator-like effector nucleases for use in vivo and in vitro genetic engineering
Classe 5
Pharmaceuticals for treating human and veterinary non-infectious diseases in the nature of inflammatory diseasesinfectious diseasesvitamin B12 deficiencydegenerative joint diseasessensory organ diseaseshereditary diseasesgenetic diseases in the nature of chromosomal abnormalitiessingle gene defectsmultifactorial and teratogenic conditionsidiopathic intracranial hypertensionaesthetic skin diseasestraumatic brain injurypsychological diseases and physiological diseases in the nature of heart disease; gene therapy productsgenetically engineered cells and tissues for medical purposesspecifically for transplant purposes; chemical reagents for medical and veterinary purposes; synthetic mRNA being nucleic acid sequences and chemical reagents for medical and veterinary purposes for correcting deficient or defective genes; cell therapy productspharmaceutical preparations for use in cell therapy for treatment of cancer; synthetic mRNA being nucleic acid sequences and related chemical reagents for medical and veterinary purposes for reprogramming cells; synthetic RNA encoding reprogramming factorspharmaceutical preparations for use in cell therapy for treatment of wounded skincancerchromosomal abnormalitiessingle gene defectsmultifactorial and teratogenic conditionsidiopathic intracranial hypertensionaesthetic skin diseasestraumatic brain injuryheart disease; products in the nature of pharmaceutical preparations for use in cell therapy for converting non-pluripotent cells into pluripotent stem cellswith or without gene-editingfor treatment of wounded skincancerchromosomal abnormalitiessingle gene defectsmultifactorial and teratogenic conditionsidiopathic intracranial hypertensionaesthetic skin diseasestraumatic brain injuryheart disease
Classe 9
Gene therapy technology in the nature of downloadable software for gene-editing that uses de novo-engineered gene-editing proteins expressed with synthetic mRNA; cell therapy productscell reprogramming technology in the nature of instruments for scientific laboratory research that use reprogramming factors expressed with synthetic mRNAcell-culture instruments in the nature of cell incubatorscell transfection instrumentscell imaging instruments
Classe 42
Pharmaceutical research and development services; pharmaceutical research and development services in the field of production of cell therapieswith or without gene-editing and with or without mRNA engineering; pharmaceutical research and development services in the field ofgene editingmRNA engineeringcell reprogramming and cell therapy development; scientific laboratory servicesin the field of stem cell production; scientific laboratory services in the field of production of stem cells and converting non-pluripotent cells into pluripotent stem cellswith or without gene-editing; scientific laboratory services in the field of gene-editing
Publicações
Histórico de despachos e eventos da marca no USPTO.
30 publicações encontradas
R.PR
REGISTERED-PRINCIPAL REGISTER
10/03/2020
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
05/02/2020
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
04/02/2020
SUPC
STATEMENT OF USE PROCESSING COMPLETE
29/12/2019
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
29/12/2019
IUAF
USE AMENDMENT FILED
18/12/2019
EISU
TEAS STATEMENT OF USE RECEIVED
18/12/2019
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
13/08/2019
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
18/06/2019
PUBO
PUBLISHED FOR OPPOSITION
18/06/2019
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
29/05/2019
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
10/05/2019
XAEC
EXAMINER'S AMENDMENT ENTERED
09/05/2019
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
09/05/2019
GNEA
EXAMINERS AMENDMENT E-MAILED
09/05/2019
CNEA
EXAMINERS AMENDMENT -WRITTEN
09/05/2019
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
10/04/2019
GNFR
FINAL REFUSAL E-MAILED
10/04/2019
CNFR
FINAL REFUSAL WRITTEN
10/04/2019
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
19/02/2019
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
19/02/2019
ALIE
ASSIGNED TO LIE
18/02/2019
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
12/02/2019
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
27/10/2018
GNRT
NON-FINAL ACTION E-MAILED
27/10/2018
CNRT
NON-FINAL ACTION WRITTEN
27/10/2018
DOCK
ASSIGNED TO EXAMINER
25/10/2018
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
12/07/2018
NWAP
NEW APPLICATION ENTERED
10/07/2018
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace F ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.